Peritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: An overview

World Journal of Gastrointestinal Oncology

Volumn 6, Issue 9, 2014, Pages 407-412

  Arjona Sánchez, Alvaro ^a   Medina Fernández, Francisco Javier ^a   Muñoz Casares, Francisco Cristobal ^a   Casado Adam, Angela ^a   Sánchez Hidalgo, Juan Manuel ^a   Rufián Peña, Sebastián ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Carcinomatosis peritoneal; Colon cancer; Cytoreduction; Intraperitoneal chemotherapy; Peritonectomy

Indexed keywords

EID: 84942502615     PISSN: None     EISSN: 19485204     Source Type: Journal    
DOI: 10.4251/wjgo.v6.i10.407     Document Type: Article

References (36)

1. [1].Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006; 243: 212-222 [PMID: 16432354 DOI: 10.1097/01.sla.0000197702.46394.16]
2. [2].Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, Frangois Y, Vignal J, Gilly FN. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88: 358-363 [PMID: 10640968 DOI: 10.1002/(SIC I)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O]
3. [3].Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, Ferron G, Guilloit JM, Meeus P, Goere D, Bonas- tre J. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27: 681-685 [PMID: 19103728 DOI: 10.1200/JCO.2008.19.7160]
4. [4].Elias D, Benizri E, Di Pietrantonio D, Menegon P, Malka D, Raynard B. Comparison of two kinds of intraperito- neal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol 2007; 14: 509-514 [PMID: 17096054 DOI: 10.1245/ s10434-006-9167-9]
5. [5].Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221: 29-42 [PMID: 7826158 DOI: 10.1097/00000658-19950100 0-00004]
6. [6].Ung L, Chua TC, Morris DL. Peritoneal metastases of lower gastrointestinal tract origin: a comparative study of patient outcomes following cytoreduction and intraperitoneal chemotherapy. J Cancer Res Clin Oncol 2013 Sep 11; Epub ahead of print [PMID: 24022087 DOI: 10.1007/s00432-013-1517-y]
7. [7].Cotte E, Passot G, Gilly FN, Glehen O. Selection of patients and staging of peritoneal surface malignancies. World J Gas- trointest Oncol 2010; 2: 31-35 [PMID: 21160814 DOI: 10.4251/ wjgo.v2.i1.31]
8. [8].Riss S, Mohamed F, Dayal S, Cecil T, Stift A, Bachleitner- Hofmann T, Moran B. Peritoneal metastases from colorectal cancer: patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2013; 39: 931-937 [PMID: 23810280 DOI: 10.1016/ j.ejso.2013.06.001]
9. [9].Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-3743 [PMID: 14551293 DOI: 10.1200/JCO.2003.04.187]
10. [10].Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dube P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperi- toneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010; 28: 63-68 [PMID: 19917863 DOI: 10.1200/JCO.2009.23.9285]
11. [11]. Cotte E, Passot G, Mohamed F, Vaudoyer D, Gilly FN, Glehen O. Management of peritoneal carcinomatosis from colorectal cancer: current state of practice. Cancer J 2009; 15: 243-248 [PMID: 19556911 DOI: 10.1097/PPO.0b013e3181a58d67]
12. [12].Valle M, Garofalo A. Laparoscopic staging of peritoneal surface malignancies. Eur J Surg Oncol 2006; 32: 625-627 [PMID: 16822641 DOI: 10.1016/j.ejso.2006.03.015]
13. [13]. Chua TC, Morris DL, Saxena A, Esquivel J, Liauw W, Doer- fer J, Germer CT, Kerscher AG, Pelz JO. Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol 2011; 18: 1560-1567 [PMID: 21203904 DOI: 10.1245/s10434-010-1522-1]
14. [14].Elias D, Benizri E, Pocard M, Ducreux M, Boige V, Lasser P. Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur J Surg Oncol 2006; 32: 632-636 [PMID: 16621428 DOI: 10.1016/ j.ejso.2006.03.013]
15. [15].Kianmanesh R, Scaringi S, Sabate JM, Castel B, Pons- Kerjean N, Coffin B, Hay JM, Flamant Y, Msika S. Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver me- tastases. Ann Surg 2007; 245: 597-603 [PMID: 17414609 DOI: 10.1097/01.sla.0000255561.87771.11]
16. [16].Elias D, Liberale G, Vernerey D, Pocard M, Ducreux M, Boige V, Malka D, Pignon JP, Lasser P. Hepatic and extrahe- patic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005; 12: 900-909 [PMID: 16184442 DOI: 10.1245/ASO.2005.01.010]
17. [17].da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg 2006; 203: 878-886 [PMID: 17116556 DOI: 10.1016/j.jamcollsurg.2006.0 8.024]
18. [18].Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995; 221: 124-132 [PMID: 7857141 DOI: 10.1097/00000658-199502000-00002]
19. [19].Chua TC, Yan TD, Ng KM, Zhao J, Morris DL. Significance of lymph node metastasis in patients with colorectal cancer peritoneal carcinomatosis. World J Surg 2009; 33: 1488-1494 [PMID: 19412567 DOI: 10.1007/s00268-009-0059-6]
20. [20]. Esquivel J, Averbach A, Chua TC. Laparoscopic cytoreduc- tive surgery and hyperthermic intraperitoneal chemotherapy in patients with limited peritoneal surface malignancies: feasibility, morbidity and outcome in an early experience. Ann Surg 2011; 253: 764-768 [PMID: 21475017]
21. [21].Esquivel J, Averbach A. Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma Peritonei of Appendiceal Origin. Gastroenterol Res Pract 2012; 2012: 981245 [PMID: 22567001 DOI: 10.1155/2012/981245]
22. [22].Fish R, Selvasekar C, Crichton P, Wilson M, Fulford P, Renehan A, O'Dwyer S. Risk-reducing laparoscopic cyto- reductive surgery and hyperthermic intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasm: early outcomes and technique. Surg Endosc 2014; 28: 341-345 [PMID: 24061624]
23. [23].Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J 2009; 15: 216-224 [PMID: 19556908 DOI: 10.1097/ PPO.0b013e3181a58d95]
24. [24].Elias D, Delperro JR, Sideris L, Benhamou E, Pocard M, Baton O, Giovannini M, Lasser P. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 2004; 11: 518-521 [PMID: 15123461 DOI: 10.1245/ASO.2004.09.008]
25. [25].Losa F, Barrios P, Salazar R, Torres-Melero J, Benavides M, Massuti T, Ramos I, Aranda E. Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin. Clin Transl Oncol 2014; 16: 128-140 [PMID: 23740133 DOI: 10.1007/s12094-013- 1053-x]
26. [26].Verhulst J. Effects of bevacizumab and hyperthermia in a rodent model of hyperthermic intraperitoneal chemotherapy (HIPEC). Int J Hyperthermia 2013; 29: 62-70 [PMID: 23311379 DOI: 10.3109/02656736.2012.753738]
27. [27]. Passot G, Dupre A, Rivoire M, Mohamed F, Bakrin N, Gle- hen O. Intraperitoneal bevacizumab combined with cytore- ductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model. Clin Transl Oncol 2012; 14: 931-936 [PMID: 22855172 DOI: 10.1007/s12094-012-0888-x]
28. [28].Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ. Cytoreductive surgery and hyperthermic intraperi- toneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer 2010; 116: 3756-3762 [PMID: 20564081 DOI: 10.1002/cncr.25116]
29. [29].Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15: 2426-2432 [PMID: 18521686 DOI: 10.1245/s10434-008-9966-2]
30. [30].de Cuba EM, Kwakman R, Knol DL, Bonjer HJ, Meijer GA, Te Velde EA. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and metaanalysis of observational studies. Cancer Treat Rev 2013; 39: 321-327 [PMID: 23244778 DOI: 10.1016/j.ctrv.2012.11.003]
31. [31].Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi- institutional study. J Clin Oncol 2004; 22: 3284-3292 [PMID: 15310771 DOI: 10.1200/JCO.2004.10.012]
32. [32]. Bijelic L, Yan TD, Sugarbaker PH. Treatment failure following complete cytoreductive surgery and perioperative intra- peritoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms. J Surg Oncol 2008; 98: 295-299 [PMID: 18726900 DOI: 10.1002/jso.21084]
33. [33].Shen P, Thai K, Stewart JH, Howerton R, Loggie BW, Russell GB, Levine EA. Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients. Ann Surg Oncol 2008; 15: 3422-3432 [PMID: 18784963 DOI: 10.1245/ s10434-008-0127-4]
34. [34].Yan TD, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care? Ann Surg 2008; 248: 829-835 [PMID: 18948811 DOI: 10.1097/SLA.0b013e31818a15b5]
35. [35].Quenet F, Goere D, Mehta SS, Roca L, Dumont F, Hessissen M, Saint-Aubert B, Elias D. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg 2011; 254: 294-301 [PMID: 21772129 DOI: 10.1097/SLA.0b013e3182263933]
36. [36].Elias D, Honore C, Dumont F, Ducreux M, Boige V, Malka D, Burtin P, Dromain C, Goere D. Results of systematic second- look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2011; 254: 289-293 [PMID: 21709543 DOI: 10.1097/SLA.0b013e31822638f6]